Combination of
Bupropion Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Zonisamide Sulfonamide anticonvulsant
Legal status
Legal status
  • Investigational

Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.[1] It is being developed by Orexigen Therapeutics. It is currently at phase II testing.[2][3] The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments.[4] When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.

Empatic was called Excalia before its name was changed.[5]

See also


This article is issued from Wikipedia - version of the 10/28/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.